Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MERCK SHARP & DOHME CORP. et al v. MYLAN PHARMACEUTICALS INC. et al
Case Number:
2:09-cv-06383
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
April 27, 2012
Merck Defeats Mylan's Challenge To Zetia, Vytorin Patent
A Merck & Co. Inc. unit prevailed Friday in a patent suit against Mylan Pharmaceuticals Inc. over its generic versions of cholesterol drugs Zetia and Vytorin, with a New Jersey federal judge ruling valid Merck's patent on an active ingredient of the drugs.
-
May 19, 2011
CORRECTED: Mylan's Inequitable Conduct Claim Axed In Vytorin IP Suit
Schering Corp. on Tuesday won the dismissal of an inequitable conduct counterclaim by Mylan Pharmaceuticals Inc. in a ruling in Schering's lawsuit accusing the generic-drug maker of infringing its patents on cholesterol drug Vytorin. (A previous version of this article incorrectly stated that a ruling had been made on Mylan's antitrust counterclaims.)